Niox
Generated by Meeveem AI
"The global leader in point of care FeNO testing for asthma diagnosis and management"
Oxford
•51 - 250 Employees
•Medical Devices & Wearables
About Niox
NIOX Group plc develops medical devices for asthma diagnosis and management. Their flagship product, NIOX VERO, measures fractional exhaled nitric oxide (FeNO) levels, a biomarker of airway inflammation. This non-invasive test provides healthcare professionals with accurate results in real time, enabling better treatment decisions for patients in primary and secondary care settings. With over 55 million tests performed in more than 50 countries, NIOX has become the device of choice for clinical research worldwide. The company supports healthcare professionals with training, educational resources, and customer service, empowering physicians to transform asthma care through evidence based diagnostics.
Illustrative visual - may not reflect the actual offering.
Illustrative visual - may not reflect the actual offering.
84
Team Members
2006
Founded
Public
Funding
Hybrid
Work Environment
Our Vision
A world where every person with asthma has access to accurate airway inflammation measurement, enabling personalised treatment and dramatically improved quality of life for millions suffering from respiratory disease.
Our Mission
At NIOX, our mission is to improve asthma diagnosis and management by greater patient access to FeNO testing.